NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT03157128 2025-10-20LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 3 FDA
NCT04985604 2025-10-02Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid TumorsDay One Biopharmaceuticals, Inc.Phase 2 Terminated23 enrolled 15 charts
NCT03690388 2025-09-25A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyExelixisPhase 3 Active not recruiting187 enrolled 13 charts 1 FDA
NCT04731467 2024-12-27A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid TumorsPurple Biotech Ltd.Phase 1/2 Completed79 enrolled
NCT05500508 2024-12-24Oral AMXT 1501 Dicaprate in Combination With IV DFMOAminex Therapeutics, Inc.Phase 1/2 Terminated15 enrolled
NCT00295763 2015-03-18A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.SanofiPhase 3 Completed61 enrolled
NCT00121628 2013-10-09A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid CancerAmgenPhase 2 Completed184 enrolled
NCT01100619 2013-09-19A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid TumorsExelixisPhase 1 Completed40 enrolled
NCT00451880 2011-10-13Study of XL281 in Adults With Solid TumorsExelixisPhase 1 Completed180 enrolled